Posts

LUNG CANCER: Anti-PD-1 therapy in the frontline

,
SHAFAQNA- Successes with the anti-PD-1 antibodies pembrolizumab and nivolumab in the second-line treatment of advanced-stage non-small-cell lung cancer (NSCLC) have inevitably led to trials in the first-line setting. Results from three such…